Ingrid Meinl Selected Research

Acute-Phase Proteins (Acute-Phase Protein)

6/2020

Neurological phenotypes in patients with NLRP3-, MEFV-, and TNFRSF1A low-penetrance variants.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ingrid Meinl Research Topics

Disease

11	Multiple Sclerosis 01/2023 - 09/2011
6	Relapsing-Remitting Multiple Sclerosis 01/2021 - 09/2011
2	Progressive Multifocal Leukoencephalopathy 01/2016 - 09/2013
1	Agammaglobulinemia (Hypogammaglobulinemia) 01/2021
1	Neuromyelitis Optica (Devic's Disease) 01/2021
1	Fever (Fevers) 06/2020
1	Anemia 07/2014
1	Thrombocytopenia (Thrombopenia) 07/2014
1	Melanoma (Melanoma, Malignant) 02/2012

Drug/Important Bio-Agent (IBA)

8	Natalizumab (Tysabri)FDA Link 01/2021 - 09/2011
5	Fingolimod Hydrochloride (FTY720)FDA Link 01/2020 - 02/2012
3	N-acetyltalosaminuronic acid (NAT)IBA 11/2014 - 09/2011
2	ocrelizumabIBA 01/2023 - 01/2021
1	B-Cell Activating FactorIBA 01/2023
1	AntibodiesIBA 01/2023
1	LigandsIBA 01/2023
1	nitazoxanide (NTZ)FDA Link 01/2021
1	Rituximab (Mabthera)FDA Link 01/2021
1	Immunoglobulin M (IgM)IBA 01/2021
1	Immunoglobulins (Immunoglobulin)IBA 01/2021
1	Acute-Phase Proteins (Acute-Phase Protein)IBA 06/2020
1	Biomarkers (Surrogate Marker)IBA 09/2013
1	Sphingosine-1-Phosphate ReceptorsIBA 02/2012
1	GadoliniumIBA 02/2012
1	Glatiramer Acetate (Copaxone)FDA Link 09/2011

Therapy/Procedure

2	Aftercare (After-Treatment) 01/2021 - 02/2012
1	Therapeutics 09/2011